ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals Inc (ALXN)

182,50
0,00
(0,00%)
À la fermeture: 03 Janvier 10:00PM
182,50
0,00
( 0,00% )
Après les heures de négociation: -

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
182,50
Prix Achat
183,00
Prix Vente
185,00
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
182,50
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

ALXN Dernières nouvelles

Moderna Set to Join S&P 500

Moderna Set to Join S&P 500 PR Newswire NEW YORK, July 15, 2021 NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the...

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized My...

– Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as...

Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Honeywell International Inc. (Nasdaq: HON), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX...

Caelum & Alexion Present Additional Phase 2 Data Reinforcing Safety & Tolerability of CAEL-101 in AL Amyloidosis at the Europ...

- Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children & Adolescents with Paroxysmal Nocturnal Hemog...

 – With this approval, ULTOMIRIS is the first and only medicine approved in the U.S. to treat children and adolescents with PNH – – Approval based on interim results from Phase 3 study showing...

Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

- Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 in AL amyloidosis - - Phase 3 studies of CAEL-101 in AL amyloidosis are underway - Caelum Biosciences and...

Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

– Long-term data evaluate the effectiveness of ULTOMIRIS® (ravulizumab-cwvz) in reducing the risk of thrombosis in PNH, the primary cause of organ damage and premature death in untreated patients...

Alexion Shareholders Approve Acquisition by AstraZeneca

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special...

Alexion Reports First Quarter 2021 Results

1Q21 total revenues of $1,636.5 million, a 13% increase over 1Q20 1Q21 GAAP diluted EPS of $2.86; non-GAAP diluted EPS of $3.52 Completed enrollment in Phase 3 studies of ULTOMIRIS®...

UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ALXN - Frequently Asked Questions (FAQ)

What is the current Alexion Pharmaceuticals share price?
The current share price of Alexion Pharmaceuticals is US$ 182,50
What is the 1 year trading range for Alexion Pharmaceuticals share price?
Alexion Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BLRXBioLineRx Ltd
US$ 0,58
(126,92%)
3,56M
CHEKCheck Cap Ltd
US$ 1,9899
(72,29%)
9,95M
TGLTreasure Global Inc
US$ 0,298
(57,26%)
18,4M
MFImF International Ltd
US$ 1,10
(51,14%)
568,97k
MGOLMGO Global Inc
US$ 0,7575
(28,17%)
6,16M
MARXUMars Acquisition Corporation
US$ 2,85
(-25,00%)
1,05k
SKYESkye Bioscience Inc
US$ 2,42
(-15,09%)
833
HWHHWH International Inc
US$ 0,5796
(-10,69%)
77,43k
IPHAInnate Pharma SA
US$ 1,70
(-9,09%)
500
BHILBenson Hill Inc
US$ 2,15
(-8,90%)
1,06k
TGLTreasure Global Inc
US$ 0,296
(56,20%)
18,4M
IVPInspire Veterinary Partners Inc
US$ 0,2591
(25,65%)
13,75M
PLUGPlug Power Inc
US$ 2,32
(-0,43%)
10,95M
ADTXAditxt Inc
US$ 0,2075
(6,41%)
10,18M
CHEKCheck Cap Ltd
US$ 1,9999
(73,15%)
9,95M
Aucune Discussion Trouvée
Ajouter une Discussion